Related content

Contribution of CYP2C9 to variability in vitamin K antagonist metabolism

By Daly Ann K   King Barry P  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 2, Iss. 1, 2006-02 ,pp. : 3-15

Informa Healthcare

Access to resources Recommend Favorite

CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population

By Scott Stuart A   Edelmann Lisa   Kornreich Ruth   Erazo Monica   Desnick Robert J  

Pharmacogenomics, Vol. 8, Iss. 7, 2007-07 ,pp. : 721-730

Future Medicine

Access to resources Recommend Favorite

Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia

By Jakovski K.   Nestorovska A. Kapedanovska   Labacevski N.   Dimovski A.J.  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 68, Iss. 11, 2013-11 ,pp. : 893-898

Govi-Verlag

Access to resources Recommend Favorite

Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

By Wennerholm Agneta   Nordmark Anna   Pihlsgård Maria   Mahindi Margarita   Bertilsson Leif   Gustafsson Lars  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 539-546

Springer Publishing Company

Access to resources Recommend Favorite

Allele Frequency Distributions of the Drug Metabolizer Genes CYP2C9*2, CYP2C9*3, and CYP2C19*17 in the Buginese Population of Indonesia

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 12, Iss. 4, 2014-12 ,pp. : 236-239

Bentham Science Publishers

Access to resources Recommend Favorite